Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome

American Journal of Medical Genetics, Part A

Volumn 146, Issue 16, 2008, Pages 2164-2168

  Hoffman, William H ^a   Jain, Alka ^b   Chen, Harold ^c   Fedarko, Neal S ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; OCTREOTIDE; PHOSPHATE; PHOSPHORUS;

BONE DENSITY; CASE REPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC LINEAR SEBACEOUS NEVUS SYNDROME; HYPOPHOSPHATEMIC RICKETS; LETTER; MALE; MUSCULOSKELETAL DISEASE; NORMAL VALUE; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PRIORITY JOURNAL; SCHOOL CHILD; SEBACEOUS NEVUS; SKIN SURGERY; STRESS FRACTURE; TREATMENT OUTCOME;

ADOLESCENT; CALCITRIOL; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTORS; GLYCOPROTEINS; HUMANS; HYPOPHOSPHATEMIA; MALE; NEVUS SEBACEOUS OF JADASSOHN; OCTREOTIDE; PHOSPHOPROTEINS; PHOSPHORUS;

EID: 49449085022     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32395     Document Type: Letter

References (28)

1. Barthel TK, Mathern DR, Whitfield GK, Haussler CA, Hopper HA IV, Hsieh JC, Slater SA, Hsieh G, Kaczmarska M, Jurutka PW, Kolek OI, Ghishan FK, Haussler MR. 2007. 1-25-dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 103:381-388.
2. Bouthors J, Vantyghem MC, Manouvrier-Hanu S, Soudan B, Proust E, Happle R, Piette F. 2006. Phacomatosis pigmentokeratotica associated with hypophosphataemic rickets, pheochromocytoma and multiple basal cell carcinomas. Br J Dermatol 155:225-226.
3. Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS. 2004. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): Implications for phosphaturia and rickets. J Endocrinol 183:R1-R9.
4. Carey DE, Drezner MK, Hamdan JA, Mange M, Ahmad MS, Mubarak S, Nyhan WL. 1986. Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: A variant of tumor-induced osteomalacia. J Pediatr 109:994-1000.
5. Dobbie H, Unwin RJ, Faria NJ, Shirley DG. 2008. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 23:30-33.
6. Econs MJ, Drezner MK. 1994. Tumor-induced osteomalacia - Unveiling a new hormone. N Engl J Med 330:1679-1681.
7. Elston MS, Stewart IJ, Clifton-Bligh R, Conaglen JV. 2007. A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: Description of the biochemical response of FGF23 to octreotide therapy and surgery. Bone 40:236-241.
8. Eriksson B, Oberg K. 1999. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook. Ann Oncol 10:S31-S38.
9. Garabedian M. 2007. Regulation of phosphate homeostasis in infants, children, and adolescents, and the role of phosphatonins in this process. Curr Opin Pediatr 19:488-491.
10. Garcia de la Torre N, Waas JAH, Turner HE. 2002. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol 57:425-441.
11. Heike CL, Cunningham ML, Steiner RD, Wenkert D, Hornung RL, Gruss JS, Gannon FH, McAlister WH, Mumm S, Whyte MP. 2005. Skeletal changes in epidermal nevus syndrome: Does focal bone disease harbor clues concerning pathogenesis. Am J Med Genet Part A 139A:67-77.
12. Hoffman WH, Jueppner HW, DeYoung BR, O'Dorisio MS, Given KS. 2005. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet Part A 134A:233-236.
13. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW. 2004. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89:4158-4161.
14. Kousseff BG. 1992. Hypothesis: Jadassohn nevus phakomatosis: A paracrinopathy with variable phenotype. Am J Med Genet 43:651-661.
15. Lattuada D, Casnici C, Venuto A, Marelli O. 2002. The apoptotic effect of somatostatin analogue SMS 201-992 on human lymphocytes. J Neuroimmunol 133:211-216.
16. Marsell R, Krajisnik T, Goransson H, Ohlsson C, Ljunggren O, Larsson TE, Jonsson KB. 2008. Gene expression analysis of kidneys from transgenic mice expressin fibroblast growth factor-23. Nephrol Dial Transplant 23:827-833.
17. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS. 2008. Degradation of MEPE, DMP1 and release of SIBLING ASARM-peptides (minhibins). ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757-1772.
18. Rowe PSN. 2004. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15:264-281.
19. Rowe PSN, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL. 2000. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68.
20. Rowe PSN, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Nawab S, Chen D, Drezner MK, Quarles LD, Mundy GR. 2004. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319.
21. Rowe PSN, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE. 2005. Surface plasmon resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: A model for impaired mineralization in X-linked rickets (HYP). Bone 36:33-46.
22. Saraswat A, Dogra S, Bansali A, Kumar B. 2003. Phakomatosis pigmentokeratotica associated with hypophosphatemic vitamin D-resistant rickets: Improvement in phosphate homeostasis after partial laser ablation. Br J Dermatol 148:1074-1076.
23. Sommer S, Berndt T, Craig T, Kumar R. 2007. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 103:497-503.
24. Vidaurri-de la Cruz H, Tamayo-Sanchez L, Duran-McKinster C, de la Luz Orozco-Covarrubias M, Ruiz-Maldonado R. 2004. Epidermal nevus syndromes: Clinical findings in 35 patients. Pediatr Dermatol 21:432-439.
25. White KE, Larsson TE, Econs MJ. 2006. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: Frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 27:221-241.
26. Yamamoto T, Imanishi Y, Kinoshita E, Nakagomi Y, Shimizu N, Miyauchi A, Satomura K, Koshiyama H, Inaba M, Nishizawa Y, Juppner H, Ozono K. 2005. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. Bone Miner Metab 23:231-237.
27. Zimering MB, Caldarella FA, White KE, Econs MJ. 2005. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr Pract 11:108-114.
28. Zeger MD, Adkins D, Fordham LA, White KE, Schoenau E, Rauch F, Loechner KJ. 2007. Hypophosphatemic rickets in opsismodysplasia. J Pediatr Endocrinol Metab 20:79-86.